Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated withJAK2V617F or calreticulin mutations-Reference-Cited by-同舟云学术

Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated withJAK2V617F or calreticulin mutations

Published:2016-01-11 Issue:8 Volume:69 Page:713-719
ISSN:0021-9746
Container-title:Journal of Clinical Pathology
language:en
Short-container-title:J Clin Pathol

Author:

Turakhia Samir K,Murugesan Gurunathan,Cotta Claudiu V,Theil Karl S

Publisher

BMJ

Subject

General Medicine,Pathology and Forensic Medicine

Reference25 articles.

1. Molecular pathways: BCR-ABL;Cilloni;Clin Cancer Res,2012

2. The peripheral blood in chronic granulocytic leukaemia. Study of 50 untreated Philadelphia-positive cases;Spiers;Scand J Haematol,1977

3. Every case of essential thrombocythemia should be tested for the Philadelphia chromosome;Rice;Am J Hematol,2005

4. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients: clinical perspectives;Blickstein;Blood,1997

5. Philadelphia chromosome and/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukemia type of myeloproliferation;Pajor;Histopathology.,2003

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins;Cancers;2024-01-11

2. Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology;Cells;2023-03-20

3. Liver cancer concurrent with chronic myelocytic leukemia and extreme thrombocytosis: a rare case report;Journal of International Medical Research;2022-09

4. Coexistence ofJAK2orCALRmutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors;International Journal of Laboratory Hematology;2018-03-06

5. Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors;OncoTargets and Therapy;2017-07